Therefore, in addition to helping understand the regulation of EGFR in cancer cells, our finding of MDM2 as a negative regulator of DYRK1A may also bear implications in the management of the conditions associated with DYRK1A overexpression. This evidence concerns the gene EGFR and cancer.